NCT03725605View on ClinicalTrials.gov

LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04)

PHASE2CompletedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

December 28, 2018

Primary Completion Date

July 2, 2021

Study Completion Date

October 11, 2021

Conditions

Soft Tissue Sarcoma

Interventions

COMBINATION_PRODUCT

LTX-315 and TILs

Intratumoural injection of LTX-315 and infusion of TILs

Trial Locations (1)

DK-2730

Herlev Hospital, Copenhagen

Sponsors

Lead Sponsor

Lytix Biopharma AS

All Listed Sponsors

collaborator

Herlev Hospital

OTHER

lead

Lytix Biopharma AS

INDUSTRY

NCT03725605 - LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04) | Biotech Hunter | Biotech Hunter